Published DateClear

Start Date

End Date

Category

• Pipeline2
• Research1

Organizations

• Bausch + Lomb66
• Eyes On Eyecare51
• Alcon, Inc.45
• American Optometric Association37
• Harrow29
• Glaukos27
• Topcon Healthcare25
• Regeneron23
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• Clinical Trials3
• Inherited Retinal Disease3
• Retina3
• FDA2
• Cell Therapy2
• Retinitis Pigmentosa2
• AMD1
• Partnership1

• Organizations: BlueRock Therapeutics✕

Clear all

Pipeline

FDA grants Orphan Drug designation to BlueRock's RP cell therapy

Marks second designation for OpCT-001; includes tax credits for qualified clinical testing and, if approved, 7 years of U.S. market exclusivity.

Pipeline

FDA grants IND clearance for BlueRock's primary photoreceptor disease cell therapy

New status paves the way for a phase 1/2a trial to evaluate the safety and efficacy of an induced pluripotent cell-derived candidate.

Research

Foundation Fighting Blindness partners with BlueRock Therapeutics on IRD study

Collaboration will add a new cohort to the nonprofit’s Uni-Rare natural history study.